Video

Foster a ‘Powerful Team’ Between Patients and Cancer Clinicians

Author(s):

Knowledge and open communication are key to creating a competent cancer care team and ensuring better outcomes.

After receiving a breast cancer diagnosis, there are no wrong questions to ask your care team, explained Dr. Igor Makhlin, assistant professor of medicine at Penn Medicine.

In a recent interview with CURE® ahead of the University of Pennsylvania Abramson Cancer Center’s 25th Life After Breast Cancer conference, Makhlin explained that when patients and their loved ones have a solid understanding of the disease and treatments, they can better express their values and goals, and therefore build a “powerful team” between the patient and clinicians.

Transcription:

One of the main messages I'd love for patients to come away with from conferences like Life After Breast Cancer is that communication is so important, and knowledge is really power. Particularly for patients first appointments, when they're newly diagnosed, whether it's early-stage or metastatic, asking a lot of questions, there is no wrong question to ask. The more you know, and the more you can express what your values are, and what is most important to you, I think that the more powerful the team will be between the patient and the oncology team, and I think the more happy patients will be with the types of treatments they receive and the outcomes. And so really keeping good communication.

The other thing I would say is that this is a really exciting time for breast cancer research and treatment. And we are I feel like just at the tip of the iceberg for where we're headed, which is more targeted therapy, less toxic therapy and hopefully much better outcomes in the near future.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content